LDS/Medical Tests/ANKK1/DRD2

ANKK1/DRD2

Dopamine receptor 2 (DRD2) is one of the four dopamine receptor actively involved in dopamine regulation. Dopamines are neurotransmitters that control cognition, emotion, locomotor activity, and other endocrine functions. Dysfunction in dopamine signaling is found in many neurologic pathological conditions such as Parkinson’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and opioid addiction.

Several genetic variations have been associated with DRD2 reduced receptor function. Among the most common is the Taq1A (32806C>T; rs1800497). This variant is located downstream of the DRD2 gene within the ankyrin repeat of the ANKK1 gene. The presence of the Taq1A T variant defines the A1 allele that is associated with a reduced DRD2 gene expression and function.

The Taq1A A1 allele (32806C>T) has been shown to be associated with nicotine dependence and the efficacy of bupropion and nicotine replacement therapy. Therefore, smokers carrying the normal DRD2 phenotype (A2/A2 genotype) using bupropion for smoking cessation are three times more likely to be abstinent at the end of treatment than non-carriers of this genotype.

Smokers with the Taq1A T variant allele (A1) seem to derive greater benefits from nicotine replacement therapies. Antipsychotic agents have been associated with hyperprolactinemia and tardive dyskinesia (TD). TD-positive patients taking antipsychotics have a higher A2 allele frequency, while A1 allele is overrepresented among those experiencing hyperprolactinemia.

Another function of the DRD2/ANKK1-TaqIA gene is in obesity and food intake as it indirectly effects food intake. The Taq1A T variant allele is often tested for obesity as it is more prevalent in obese people.

* Evaluate nicotine addiction and dependence * Monitor bupropion and nicotine replacement therapy
  • The presence of the Taq1A T variant defines the A 1 allele that is associated with a reduced DRD2 gene expression and function
  • Smokers carrying the normal DRD2 phenotype (A2/A2 genotype) using bupropion for smoking cessation are three times more likely to be abstinent at the end of treatment than non-carriers of this genotype
  • Smokers with the Taq1A T variant allele (A1) seem to derive greater benefits from nicotine replacement therapies

Taq1A G/G

PCR with Allele specific primer extension (ASPE). Real-time PCR with ASPE.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices, Buccal swab

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
  • Buccal swab is stable for longer.
Nicotine, Prolactin levels in hyperprolactinemia.
3-7 days
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login